[Federal Register Volume 81, Number 96 (Wednesday, May 18, 2016)]
[Notices]
[Pages 31250-31251]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-11661]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-up Exclusive License: Development of
Virus Like Particles for the Treatment of Breast Cancer, Lung Cancer,
Melanoma, Pancreatic Cancer, and Hepatocellular Cancer
AGENCY: National Institutes Of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7, that the National Cancer Institute, National Institutes of
Health, Department of Health and Human Services, is contemplating the
grant of a Start-Up Exclusive Patent License to practice the inventions
embodied in the following patent applications to Chimeron Bio
Corporation, a company incorporated under the laws of Delaware and
having an office in Philadelphia, PA.
Intellectual Property: U.S. Provisional Patent Application No.: 61/
615,687 Entitled ``Delivery of Packaged RNA in Mammalian Cells'' HHS
Ref. No.: E-264-2011/0-US-01 Filed March 26, 2012; International Patent
Application No.: PCT/US2013/031876 Entitled ``Delivery of Packaged RNA
in Mammalian Cells'' HHS Ref. No.: E-264-2011/0-PCT-02 Filed March 15,
2013; Australian Patent Application No.: 2013-240248 Entitled
``Delivery of Packaged RNA in Mammalian Cells'' HHS Ref. No.: E-264-
2011/0-AU-03 Filed October 17, 2014; European Patent Application No.:
13712661.1 Entitled ``Delivery of Packaged RNA in Mammalian Cells'' HHS
Ref. No.: E-264-2011/0-EP-04 Filed October 24, 2014; Japanese Patent
Application No.: 2015-503322 entitled ``Delivery of Packaged RNA in
Mammalian Cells'' HHS Ref. No.: E-264-2011/0-JP-05 Filed September 25,
2014; U.S. Patent Application No.: 14/388,441 Entitled Delivery of
Packaged RNA in Mammalian Cells'' HHS Ref. No.: E-264-2011/0-US-06
Filed September 26, 2014; U.S. Provisional Patent Application No.: 61/
916,394 Entitled ``Cancer Immunotherapy: Delivery HLA-11 using VLP-
Replicon'' HHS Ref. No.: E-050-2014/0-US-01 Filed December 16, 2013;
International Patent Application No.: PCT/US2014/070552 Entitled
``Cancer Immunotherapy: Delivery HLA-11 using VLP-Replicon'' HHS Ref.
No.: E-050-2014/0-PCT-02 Filed December 16, 2014;
The patent rights to these inventions have been assigned to the
Government of the United States of America.
The prospective exclusive start-up licensed territory may be
worldwide and the field of use may be limited to: ``Use of virus like
particles comprising MHCII and CD80 for the treatment of breast cancer,
lung cancer, melanoma, pancreatic cancer, and hepatocellular cancer.''
DATES: Only written comments and/or applications for a license which
are received by the NCI Technology Transfer Center on or before June 2,
2016 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated exclusive license should be
directed to: Lauren Nguyen-Antczak, Ph.D., J.D., Sr. Licensing and
Patenting Manager, Technology Transfer Center, National Cancer
Institute, 8490 Progress Drive, Riverside 5, Suite 400, Frederick, MD
21701; Telephone: (301) 624-8752; Email: [email protected].
SUPPLEMENTARY INFORMATION: The invention is directed to virus-like
particles (``VLPs'') that serve to induce transgene expression of at
least one recombinant protein of interest in specific, targeted cells.
This technology can be used to treat a variety of diseases, depending
on the cell type to be targeted. Preferably, invention VLPs may be used
to treat tumor bearing cancers, including breast cancer, lung cancer,
melanoma, pancreatic cancer, and hepatocellular cancer.
The prospective Start-Up Exclusive Patent License, which will be
royalty bearing, is being considered under the small business
initiative launched on 1 October 2011 and will comply with the terms
and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective
Start-Up Exclusive Patent License may be granted unless the NIH
receives written evidence and argument, within fifteen (15) days from
the date of this published notice, that establishes that the grant of
the license would not be consistent with the requirements of 35 U.S.C.
209 and 37 CFR part 404.7.
Complete applications for a license in the field of use filed in
response to this notice will be treated as objections to the grant of
the contemplated exclusive start-up license. Comments and objections
submitted to this notice will not be made available for public
inspection and, to the extent permitted by law, will not be released
under the Freedom of Information Act, 5 U.S.C. 552.
[[Page 31251]]
Dated: May 12, 2016.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2016-11661 Filed 5-17-16; 8:45 am]
BILLING CODE 4140-01-P